Surfactant-based drug delivery systems for treating drug-resistant lung cancer

Prabhjot Kaur, Tarun Garg, Goutam Rath, R. S.R. Murthy, Amit K. Goyal

Research output: Contribution to journalArticlepeer-review

58 Scopus citations


Among all cancers, lung cancer is the major cause of deaths. Lung cancer can be categorized into two classes for prognostic and treatment purposes: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Both categories of cancer are resistant to certain drugs. Various mechanisms behind drug resistance are over-expression of superficial membrane proteins [glycoprotein (P-gp)], lung resistance-associated proteins, aberration of the intracellular enzyme system, enhancement of the cell repair system and deregulation of cell apoptosis. Structure-performance relationships and chemical compatibility are consequently major fundamentals in surfactant-based formulations, with the intention that a great deal investigation is committed to this region. With the purpose to understand the potential of P-gp in transportation of anti-tumor drugs to cancer cells with much effectiveness and specificity, several surfactant-based delivery systems have been developed which may include microspheres, nanosized drug carriers (nanoparticles, nanoemulsions, stealth liposomes, nanogels, polymer-drug conjugates), novel powders, hydrogels and mixed micellar systems intended for systemic and/or localized delivery.
Original languageEnglish (US)
Pages (from-to)727-738
Number of pages12
JournalDrug Delivery
Issue number3
StatePublished - Mar 23 2016
Externally publishedYes

Bibliographical note

Generated from Scopus record by KAUST IRTS on 2023-10-12


Dive into the research topics of 'Surfactant-based drug delivery systems for treating drug-resistant lung cancer'. Together they form a unique fingerprint.

Cite this